Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 33,151 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Interventions: Prednisone, Placebo; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Redlands, California

Conditions: Coronavirus, COVID, ARDS, Cytokine Storm, Cytokine Release Syndrome
Interventions: SNDX-6352, Placebo; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Scottsdale, Arizona • The Bronx, New York

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for alirocumab), Atorvastatin, Placebo (for atorvastatin); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 20
States / cities: Mesa, Arizona • Tucson, Arizona • Los Angeles, California + 14 more

Conditions: Dental Pain and Sensation Disorder, Pain, Postoperative
Interventions: Gabapentin 600mg, Placebo; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 59 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Analgesia, Postoperative
Interventions: Exparel, Bupivacaine Hcl 0.25% Inj, Placebo; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: ONO-5129; Drug
Lead sponsor: Ono Pharma USA Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 67
States / cities: Birmingham, Alabama • Calera, Alabama • Huntsville, Alabama + 51 more

Conditions: Cardiac Repolarization in Healthy Subjects
Interventions: Carbidopa capsule, Moxifloxacin Tablets, USP, Placebo; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Dilworth, Minnesota

Conditions: Prostate Cancer
Interventions: tarenflurbil, adjuvant therapy; Drug · Procedure
Lead sponsor: Myrexis Inc.; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 58
States / cities: Homewood, Alabama • Anchorage, Alaska • Fresno, California + 49 more

Conditions: Primary Biliary Cirrhosis
Interventions: Obeticholic Acid (OCA), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 15
States / cities: Sacramento, California • San Diego, California • Aurora, Colorado + 11 more

Conditions: Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of, Brain Aging, Fatty Acids, Omega-3
Interventions: Alpha-Linolenic Acid (2.6 g/day), Placebo Control Group; Drug · Dietary Supplement
Lead sponsor: Michal Schnaider Beeri, Ph.D.; Other
Eligibility: 60 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Diastolic Dysfunction, Systolic Dysfunction, Diastolic Heart Failure
Interventions: Sulforaphane; Drug
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 60 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Osteoarthritis, Arthritis
Interventions: Negative Work, Stretching; Other
Lead sponsor: Washington D.C. Veterans Affairs Medical Center; Federal
Eligibility: 50 Years to 70 Years · Male only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Mitochondrial Function, Bioenergetics, Muscle Function, Aging
Interventions: Mitopure, Placebo; Dietary Supplement
Lead sponsor: Amazentis SA; Industry
Eligibility: 65 Years to 90 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Immune System Disorder (Healthy Volunteer)
Interventions: Belumosudil mesylate, Placebo; Drug
Lead sponsor: Kadmon, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Alzheimer Disease
Interventions: PF-04494700 - Low Dose Arm, PF-04494700 - High Dose Arm, Placebo Comparator; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 12
States / cities: Sun City, Arizona • Fresno, California • San Diego, California + 9 more

Conditions: Alzheimer's Disease
Interventions: Bexarotene, Placebo; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 50 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Diabetes Mellitus
Interventions: Exenatide, Exenatide matching placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 68
States / cities: Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 56 more

Conditions: Hearing Loss, Head and Neck Cancer
Interventions: Placebo, Atorvastatin; Other · Drug
Lead sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 5
States / cities: Atlanta, Georgia • Baltimore, Maryland • Bethesda, Maryland + 2 more

Conditions: Alzheimer's Disease
Interventions: SUVN-502, Placebo, Donepezil, Memantine; Drug
Lead sponsor: Suven Life Sciences Limited; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 71
States / cities: Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 56 more

Conditions: Beta-Caryophyllene
Interventions: Low Dose Beta-Caryophyllene, Medium Dose Beta-Caryophyllene, High Dose Beta-Caryophyllene, Placebo; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Stretch Marks, Striae Distensae, Cosmetic Appearance of Stretch Marks
Interventions: Placebo Vehicle Cream, Centella Asiatica Cream; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Hypertension, Cardiovascular Diseases, Diabetes
Interventions: Herbiotics Oral + Ent Probiotic, Placebo; Dietary Supplement
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Obesity, Hyperlipidemia, Hypertension
Interventions: Antioxidant diet, Antioxidant supplement, Placebo; Behavioral · Dietary Supplement
Lead sponsor: Christopher Gardner; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Ivermectin
Interventions: Ivermectin, Placebo; Drug · Other
Lead sponsor: University of Georgia; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Athens, Georgia

Search by objective public record fields.

Systemic Corticosteroids in the Perioperative Management of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia

Efficacy of Preoperative Administration of Gabapentin in 3rd Molar Dental Extraction.

Exparel vs. Bupivacaine Hydrochloride vs. Placebo for Hernia Repair

A Phase II Study to Evaluate the Effects of Oral ONO-5129 in Type 2 Diabetes Mellitus

A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects

R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES

Negative Work Exercise for the Treatment of Knee Arthritis

Bioenergetics and Muscle Function Improvement With AMAZ-02 in Elderly Skeletal Muscle (ENERGIZE Trial)

A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

Bexarotene Amyloid Treatment for Alzheimer's Disease

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

Acute Changes In Thermal Pain Response Following Single Oral Dose of Beta-Cary

Topical Centella Asiatica and the Cosmetic Appearance of Stretch Marks

Probiotic Effect on Dietary Nitrate to Plasma Nitrite Production ( OPEDNPN )

Effects of Dietary Antioxidants on Cardiovascular Risk Factors

Ivermectin and Human Immunity